Analyst: Eli Lilly considers Alzheimer's submission after phase II
Eli Lilly is so enthusiastic about its potential Alzheimer's treatment donanemab that the firm is ready to submit the drug for evaluation on the basis of data coming from two phase II trials.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
Drug candidate donanemab might potentially become the second Alzheimer's drug to be submitted to the US Food and Drug Administration within a short time span.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly skyrockets following positive Alzheimer's data
For subscribers
